To confirm the therapeutic effect of JNK inhibitor combined with dasatinib on BCR-ABL+ B-ALL in vivo, we tested the efficacy of JNK inhibitor plus dasatinib in the BCR-ABLP190 bone marrow transduction and transplantation mouse model described above. Here, ABL1 is linked to acute lymphoblastic leukemia.